135 related articles for article (PubMed ID: 37933187)
1. The roles of type 2 diabetes and obesity in disease activity and progression of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
Shinde S; Nelson DR; Mitroi J; Heaton PC; Hincapie AL; Brouwers B
Curr Med Res Opin; 2024 Jan; 40(1):59-68. PubMed ID: 37933187
[TBL] [Abstract][Full Text] [Related]
2. Non-alcoholic fatty liver disease in pediatric type 2 diabetes: Metabolic and histologic characteristics in 38 subjects.
Newfield RS; Graves CL; Newbury RO; Schwimmer JB; Proudfoot JA; Say DS; Feldstein AE
Pediatr Diabetes; 2019 Feb; 20(1):41-47. PubMed ID: 30467936
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes.
Lembo E; Russo MF; Verrastro O; Anello D; Angelini G; Iaconelli A; Guidone C; Stefanizzi G; Ciccoritti L; Greco F; Sessa L; Riccardi L; Pompili M; Raffaelli M; Vecchio FM; Bornstein SR; Mingrone G; Gastaldelli A; Capristo E
Diabetes Metab; 2022 Sep; 48(5):101363. PubMed ID: 35760372
[TBL] [Abstract][Full Text] [Related]
4. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
Kleiner DE; Brunt EM; Wilson LA; Behling C; Guy C; Contos M; Cummings O; Yeh M; Gill R; Chalasani N; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Terrault N; Kowdley K; Loomba R; Belt P; Tonascia J; Lavine JE; Sanyal AJ;
JAMA Netw Open; 2019 Oct; 2(10):e1912565. PubMed ID: 31584681
[TBL] [Abstract][Full Text] [Related]
5. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.
Reddy YK; Marella HK; Jiang Y; Ganguli S; Snell P; Podila PSB; Maliakkal B; Satapathy SK
J Clin Exp Hepatol; 2020; 10(3):245-254. PubMed ID: 32405181
[TBL] [Abstract][Full Text] [Related]
6. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of black relative to white race against non-alcoholic fatty liver disease in patients with severe obesity, independent of type 2 diabetes.
Browning MG; Khoraki J; DeAntonio JH; Mazzini G; Mangino MJ; Siddiqui MS; Wolfe LG; Campos GM
Int J Obes (Lond); 2018 Apr; 42(4):926-929. PubMed ID: 29437160
[TBL] [Abstract][Full Text] [Related]
8. Prevalence, Diagnosis, and Treatment with 3 Different Statins of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?
Sfikas G; Psallas M; Koumaras C; Imprialos K; Perdikakis E; Doumas M; Giouleme O; Karagiannis A; Athyros VG
Curr Vasc Pharmacol; 2021; 19(5):572-581. PubMed ID: 33059580
[TBL] [Abstract][Full Text] [Related]
9. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
10. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
11. Sex influences the association between appendicular skeletal muscle mass to visceral fat area ratio and non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease.
Li G; Rios RS; Wang XX; Yu Y; Zheng KI; Huang OY; Tang LJ; Ma HL; Jin Y; Targher G; Byrne CD; Pan XY; Zheng MH
Br J Nutr; 2022 Jun; 127(11):1613-1620. PubMed ID: 34176541
[TBL] [Abstract][Full Text] [Related]
12. Histopathological differences in patients with biopsy-proven non-alcoholic fatty liver disease with and without type 2 diabetes.
Aller de la Fuente R; Mora Cuadrado N; Tafur C; López Gómez JJ; Gómez de la Cuesta S; García Sánchez MC; Antolin Melero B; de Luis Román DA
Endocrinol Diabetes Nutr (Engl Ed); 2018; 65(6):354-360. PubMed ID: 29477355
[TBL] [Abstract][Full Text] [Related]
13. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
[TBL] [Abstract][Full Text] [Related]
14. Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease.
Daher S; Lev Cohen N; Massarwa M; Mahamid M; Nasser M; Hazou W; Oren R; Safadi R; Khoury T
PLoS One; 2018; 13(11):e0207479. PubMed ID: 30500848
[TBL] [Abstract][Full Text] [Related]
15. [Study on the correlation between type 2 diabetes mellitus combined with non-alcoholic steatohepatitis and aerobic exercise performance].
Zhang J; Li L; Yu HY; Li Y; Wang FM; Di FS
Zhonghua Gan Zang Bing Za Zhi; 2023 Oct; 31(10):1068-1074. PubMed ID: 38016772
[No Abstract] [Full Text] [Related]
16. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.
Pais R; Charlotte F; Fedchuk L; Bedossa P; Lebray P; Poynard T; Ratziu V;
J Hepatol; 2013 Sep; 59(3):550-6. PubMed ID: 23665288
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
Shelley K; Articolo A; Luthra R; Charlton M
BMC Gastroenterol; 2023 May; 23(1):160. PubMed ID: 37208593
[TBL] [Abstract][Full Text] [Related]
18. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes.
Bayliss J; Ooi GJ; De Nardo W; Shah YJH; Montgomery MK; McLean C; Kemp W; Roberts SK; Brown WA; Burton PR; Watt MJ
Front Endocrinol (Lausanne); 2021; 12():642432. PubMed ID: 33746906
[TBL] [Abstract][Full Text] [Related]
19. Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients.
Huang Y; Gan Q; Lai R; Wang W; Guo S; Sheng Z; Chen L; Guo Q; Cai W; Wang H; Zhao G; Cao Z; Xie Q
Front Cell Infect Microbiol; 2021; 11():733348. PubMed ID: 35111690
[TBL] [Abstract][Full Text] [Related]
20. Poor glycaemic control and ectopic fat deposition mediates the increased risk of non-alcoholic steatohepatitis in high-risk populations with type 2 diabetes: Insights from Bayesian-network modelling.
Waddell T; Namburete A; Duckworth P; Fichera A; Telford A; Thomaides-Brears H; Cuthbertson DJ; Brady M
Front Endocrinol (Lausanne); 2023; 14():1063882. PubMed ID: 36909341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
